



Media Release

April 21, 2017

MSDx Presents Poster at the 69th American Academy of Neurology Annual Meeting April 22-28, 2017

TUCSON, Ariz., April 21, 2017 – MSDx, Inc. is presenting a poster at the 69th American Academy of Neurology (AAN) Annual Meeting April 22-28, 2017 at the Boston Convention Center, Boston, Massachusetts. MSDx Director of Research, Ramesh Nayak, Ph.D. is presenting research results on a blood-based biomarker for evaluating therapeutic response in multiple sclerosis (MS) patients.

“We have discovered an extremely large (400-1000 KD) protein complex in plasma that may be a candidate pharmacodynamic marker, which is a molecule that changes in level in response to drug therapy,” explains Dr. Nayak. The company received a US patent on this novel biomarker technology referred to as **MSDx Complex-1**. This protein complex is thought to be generated by the process by which the white blood cells that cause inflammation cross the blood brain barrier. Monitoring the breakdown products of the white cell trafficking is an innovative strategy for monitoring disease activity. “The research data presented in this poster supports the idea that changes in the levels of MSDx Complex-1 aggregate into three groups that may define strong responders vs. responders vs. non-responders in multiple sclerosis patients.” This biomarker is one of a panel of proprietary blood tests being developed.

The AAN Annual Meeting is the world's largest gathering of neurologists, bringing together more than 10,000 neurology professionals across the globe to network, discuss cutting-edge research, and take part in top-rated education programming across a wide variety of topics.

About MSDx, Inc.

MSDx is a neuro-diagnostic company that discovered a novel source of blood-based biomarkers that can offer a real-time view of disease activity in the brain. The company refers to its proprietary, patented approach as **WINDOW INTO THE BRAIN™**. Multiple Sclerosis is the first disease of focus for the company. Ultimately, this technology may be applied in other neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Traumatic Brain Injury. MSDx blood tests will offer critical data that can be used by the pharmaceutical companies as tools for drug discovery and by the neurologists as blood tests for monitoring therapeutic response in their patients. Improving treatment decisions can help to slow disease progression for the patient while reducing lifelong healthcare costs.

MSDx is pursuing the development of a Laboratory Developed Tests (LDT) as well as In Vitro Diagnostic (IVD) blood tests for brain diseases. The company is in Tucson, Arizona. Please visit www.msdx.co for more information about the company and their patented technology.

Media Contact: Marie Wesselhoft, mwesselhoft@msdx.co 520-907-3267

